ABL Diagnostics S.A. is a biotechnology company specializing in innovative molecular biology tests and comprehensive solutions for microbiology diagnostics. It develops and markets proprietary assays including DeepChek® for genotyping through DNA sequencing and UltraGene® for molecular polymerase chain reaction (PCR) detection, targeting infectious diseases such as HIV drug resistance, SARS-CoV-2, tuberculosis, hepatitis B and C, HPV, and microbiome analyses via 16S/18S RNA. The company also offers integrated digital solutions like Nadis®, an electronic medical record system used in French hospitals for managing HIV and hepatitis patients, and MediaChek® clinical sample collection kits. Additional products encompass real-time syndromic PCR tests, analysis software, lab automation tools, and instruments for DNA/RNA extraction, real-time PCR systems, liquid handling robots, and next-generation sequencing. ABL Diagnostics S.A. serves academic clinical pathology laboratories, private reference labs, and researchers worldwide through its sales team and exclusive distributor network across all continents, with a significant portion of sales from exports. Headquartered in Woippy, France, it markets products from its sister company CDL Pharma and operates a U.S. subsidiary for expanded reach in the medical diagnostics sector.